scholarly journals Predictive Significance of Serum Interferon Inducible Protein Score for Response to Treatment in Systemic Sclerosis Related Interstitial Lung Disease

2020 ◽  
Author(s):  
Shervin Assassi ◽  
Ning Li ◽  
Elizabeth R. Volkmann ◽  
Maureen D. Mayes ◽  
Dennis Rünger ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Response To Treatment ◽  
Inducible Protein ◽  
Interferon Inducible Protein

scholarly journals Circulating Biomarkers of Interstitial Lung Disease in Systemic Sclerosis

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Harpreet K. Lota ◽  
Elisabetta A. Renzoni
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Disease Severity ◽  
Prospective Studies ◽  
Predictive Ability ◽  
Early Response ◽  
Response To Treatment ◽  
Circulating Biomarkers ◽  
Patients At Risk

Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with systemic sclerosis (SSc). Although a large proportion of SSc patients have only limited interstitial involvement with an indolent course, in a significant minority ILD is progressive, requiring prompt treatment and careful monitoring. One of the main challenges for the clinician treating this highly variable disease is the early identification of patients at risk of progressive ILD, while avoiding potentially toxic treatments in those whose disease is inherently stable. Easily available and repeatable biomarkers that allow estimation of the risk of ILD progression and early response to treatment are highly desirable. In this paper, we review the evidence for circulating biomarkers with potential roles in diagnosis, monitoring of disease activity, or determining prognosis. Peripheral blood biomarkers offer the advantages of being readily obtained, non-invasive, and serially monitored. Several possible candidates have emerged from studies performed so far, including SP-D, KL-6, and CCL18. Presently however, there are few prospective studies evaluating the predictive ability of prospective biomarkers after adjustment for disease severity. Future carefully designed, prospective studies of well characterised patients with ILD, with optimal definition of disease severity and outcome measures are needed.

scholarly journals Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease

2019 ◽  
Vol 15 (10) ◽  
pp. 1009-1017 ◽  
Author(s):  
Oliver Distler ◽  
Elizabeth R. Volkmann ◽  
Anna Maria Hoffmann-Vold ◽  
Toby M. Maher
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Future Perspectives
Sign in / Sign up

Export Citation Format

Share Document